NCT04560309View on ClinicalTrials.gov

Role of Glutamine as Myocardial Protector in Elective On-Pump CABG Surgery With Low EF

PHASE3CompletedINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

January 1, 2021

Primary Completion Date

October 30, 2021

Study Completion Date

November 23, 2021

Conditions
Coronary Artery BypassCardiopulmonary BypassCoronary Artery Disease
Interventions
DRUG

L-alanyl-L-glutamine dipeptide

Intravenous infusion of 0.5 mg/kgbw L-alanyl-L-glutamine dipeptide diluted in normal saline to volume of 500 mL, started after induction of anesthesia for 24 hours.

DRUG

Placebo

Intravenous infusion of 500 mL normal saline, started after induction of anesthesia for 24 hours.

Trial Locations (1)

11420

National Cardiovascular Center Harapan Kita Hospital Indonesia, Jakarta

All Listed Sponsors
lead

National Cardiovascular Center Harapan Kita Hospital Indonesia

OTHER

NCT04560309 - Role of Glutamine as Myocardial Protector in Elective On-Pump CABG Surgery With Low EF | Biotech Hunter | Biotech Hunter